Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Arrowhead Prices $36 Million Private Offering

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Arrowhead Research Corporation announced that it has priced a private offering with gross proceeds expected to be $36 million. The offering was priced at $1.83 per common share.

Approximately 14.3 million shares of common stock and 9,900 shares of series B convertible preferred stock are expected to be issued at closing. The series B preferred shares are priced at $1,000 per share, are convertible into shares of common stock at a conversion price of $1.83 per share of common stock and include no dividends or liquidation preferences. The offering is expected to close on or about May 3, 2013, subject to the satisfaction of customary closing conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock and the shares of common stock issuable upon conversion of the series B preferred.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Arrowhead Begins Trial of ARC-AAT
The company has announced that it has dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT.
Friday, July 03, 2015
Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery
The company believes the new Dynamic Polyconjugates are highly potent and may represent a dramatic improvement in duration of activity over competing technologies.
Wednesday, May 06, 2015
Arrowhead Acquires Novartis' RNAi R&D Portfolio
The acquisition includes multiple patent families covering RNAi-trigger design rules and modifications.
Friday, March 06, 2015
Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520
ARC-520 is the company’s candidate for the treatment of chronic hepatitis B virus infection.
Wednesday, July 24, 2013
Arrowhead to Present at Upcoming Scientific Conferences
Company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate.
Tuesday, May 14, 2013
Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus
Single injection induces multi-log repression of viral RNA, proteins, and viral DNA.
Wednesday, February 27, 2013
Arrowhead Research Corporation Acquires Alvos Therapeutics
Alvos previously licensed a large platform of proprietary human-derived homing peptides from MD Anderson Cancer Center (MDACC) and the method for their discovery.
Thursday, April 12, 2012
Calando Submits IND for Clinical Trial with Targeted, Nano-Delivered RNAi Therapeutic for Cancer
Arrowhead Research Corporation’s subsidiary Calando Pharmaceuticals plans to initiate a Phase I clinical trial using their lead anti-cancer compound.
Wednesday, March 19, 2008
Arrowhead Raises Additional Capital from Institutional Shareholders
A portion of the proceeds of the sale was used to increase Arrowhead's ownership in RNAi subsidiary.
Monday, August 21, 2006
Arrowhead Announces the Issuance of Patent Covering a New Approach to Targeted Therapeutics
In addition to covering applications pursued by Insert, the technology is licensed for use in RNAi therapeutics to Calando Pharmaceuticals.
Thursday, April 13, 2006
Scientific News
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Cancer Can Arise from Histone Mutations
A mutation that affects the proteins that package DNA—without changing the DNA itself—can cause a rare form of cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!